Goldline Pharmaceutical results
BSE: 544759Pharmaceuticals & BiotechnologySmall Cap
Last close ₹30.10up ₹0.12 (0.40%)
Share price at the BSE close on 23 Oct 2026. Previous close ₹29.98.
Range of traded prices from listing on 19 May 2026 to 23 Oct 2026
₹28.13Low, 21 Oct 2026₹60.00High, 19 May 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹29 Cr3,537th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 9 Jun 2026
- 7.0
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 9 Jun 2026
- 2.0
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonesince listing in May 2026
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the latest balance sheet's; the one a year before is not on record. The filing of 9 Jun 2026
- 28.9%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 9 Jun 2026
- 0.64
- Volume, BSEVolume. Shares traded on the last trading day.
- 6,000
Results for the half year to Mar 2026
Standalone: the listed company alone, without its subsidiaries. ₹ crore.Goldline Pharmaceutical annual results and balance sheet
- RevenueRevenue from operations. Money earned from selling the company's goods and services in the period.
- ₹17 Cr+24.6% on the half year beforeChange on a year ago. The change against the same half year a year before: (this half year's figure less that half year's) divided by that half year's, times 100. Left out where either figure is a loss, or across a change of basis named under the table, on the lines it affects.
- Net profitNet profit. What is left of revenue and other income after every cost, interest and tax.
- ₹2.76 Cr+103.7% on the half year beforeChange on a year ago. The change against the same half year a year before: (this half year's figure less that half year's) divided by that half year's, times 100. Left out where either figure is a loss, or across a change of basis named under the table, on the lines it affects.
- Earnings per shareEarnings per share. Profit belonging to shareholders divided by the number of shares, restated for later splits and bonuses so they do not break the line.
- ₹3.43
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax.
- 16.0%
From revenue to net profit, ₹ crore
- Revenue17
- Other income0.0
- Finance costs−0.6
- Profit before tax3.5
- Tax−0.8
- Net profit2.8
Goldline Pharmaceutical results by half year
Standalone: the listed company alone, without its subsidiaries. Latest half year to Mar 2026. Results for the half year to Sep 2026 are due by 14 Nov 2026, 45 days after it ends.Results filings and date
Revenue and net profit by half year, ₹ crore
- Revenue
- Net profit
Operating and net margin by half year, per cent
- Operating marginOperating margin. Operating profit before depreciation as a percentage of revenue: how much of each rupee of sales is left after running costs.
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax.
| ₹ crore | Sep 2025worked out | Mar 2026Filed 9 Jun |
|---|---|---|
| Revenue from operations | 13.9what Revenue from operations, Sep 2025, includes. Not filed on its own: worked out as the year to Mar 2026 the company filed, less the six months to Mar 2026. | 17.3 |
| Operating expenses. What the business spent to run itself in the period, materials, staff and other costs, before depreciation, interest and tax. | – | – |
| Materials and goods boughtCost of materials and goods. Raw materials used and goods bought for resale in the period, adjusted for the change in stock held. | 5.3 | 5.9 |
| Other incomeOther income. Income from outside the main business, such as interest on deposits, dividends received and gains on investments. | – | 0.0 |
| Finance costsFinance costs. Interest and the other costs of borrowing in the period. | 0.7 | 0.6 |
| Profit before tax | 1.9 | 3.5 |
| 0.5 | 0.8 | |
| Tax rateEffective tax rate. Tax charged as a percentage of profit before tax. | 26.8% | 21.9% |
| Net profit | 1.4 | 2.8 |
| Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. | 9.8% | 16.0% |
| Earnings per shareEarnings per share. Profit belonging to shareholders divided by the number of shares, restated for later splits and bonuses so they do not break the line. | – | ₹3.43 |
Earnings per share in rupees, restated for later splits and bonuses.
Filed results, as an XML file each
- Results for the half year to Mar 2026 (opens in a new tab)Filed 9 Jun 2026